Medication therapy and lifestyle support go hand in hand in obesity care, especially when we consider GLP-1s. The Omada Insights Lab evaluated outcomes in the Enhanced GLP-1 Care Track at one year, and found that persistence rates and weight loss surpassed published real-world estimates. Key findings include:
67% of Omada members were persistent on their medication at one year and experienced weight loss comparable to clinical trials
Average weight loss at one year in the program was 18.4% for members persistent on medication and 13.1% for members who discontinued before one year
Members completed more than 10 actions a week on average